双功能PD-1×αCD3×αCD33融合蛋白逆转急性髓系白血病的适应性免疫逃逸
研究开发了一种双功能检查点抑制性T细胞衔接抗体,将PD-1胞外域融合至αCD3.αCD33双特异性T细胞衔接器骨架,实现靶向CD33的T细胞重定向与局部免疫检查点阻断。该分子通过协同效应增强T细胞活化,对CD33+PD-L1+细胞系及患者来源AML细胞发挥高效选择性细胞毒作用,并在小鼠异种移植模型中诱导AML完全清除而无irAEs初期迹象。
要点
- PD-1ex融合增加T细胞活化,干扰素-γ升高3.3倍
- 对CD33+PD-L1+细胞系半数有效浓度为2.3-26.9 pM
- 小鼠异种移植模型中诱导AML完全清除,无体重下降等irAEs初期迹象
核心结论
- 该分子优先靶向AML细胞,而高亲和力阻断剂如临床批准抗癌药也作用于PD-L1+非AML细胞。
- 通过将T细胞衔接器的高效性与免疫检查点阻断结合于单一分子,预期可最小化全身应用免疫检查点抑制剂相关的irAEs,并认为对复发/难治性AML患者具有高治疗潜力。
研究设计与样本
- 构建双功能检查点抑制性T细胞衔接抗体,将PD-1胞外域融合至αCD3.αCD33 BiTE样骨架。
- 在体外细胞系、患者来源AML细胞(n=8)及小鼠异种移植模型中评价效果。
主要发现
- PD-1ex附着使干扰素-γ升高3.3倍。
- 对CD33+PD-L1+细胞系半数有效浓度为2.3-26.9 pM。
- 对患者来源AML细胞(n=8)发挥高效选择性细胞毒作用。
- 小鼠异种移植模型中诱导AML完全清除,无体重下降等irAEs初期迹象。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The CD33-targeting bispecific T-cell engager (BiTE) AMG 330 proved to be highly efficient in mediating cytolysis of acute myeloid leukemia (AML) cells in vitro and in mouse models. Yet, T-cell activation is correlated with upregulation of programmed cell death-ligand 1 (PD-L1) and other inhibitory checkpoints on AML cells that confer adaptive immune resistance. PD-1 and PD-L1 blocking agents may counteract T-cell dysfunction, however, at the expense of broadly distributed immune-related adverse events (irAEs). We developed a bifunctional checkpoint inhibitory T cell-engaging (CiTE) antibody that combines T-cell redirection to CD33 on AML cells with locally restricted immune checkpoint blockade. This is accomplished by fusing the extracellular domain of PD-1 (PD-1ex), which naturally holds a low affinity to PD-L1, to an αCD3.αCD33 BiTE-like scaffold. By a synergistic effect of checkpoint blockade and avidity-dependent binding, the PD-1ex attachment increases T-cell activation (3.3-fold elevation of interferon-γ) and leads to efficient and highly selective cytotoxicity against CD33+PD-L1+ cell lines (50% effective concentration = 2.3-26.9 pM) as well as patient-derived AML cells (n = 8). In a murine xenograft model, the CiTE induces complete AML eradication without initial signs of irAEs as measured by body weight loss. We conclude that our molecule preferentially targets AML cells, whereas high-affinity blockers, such as clinically approved anticancer agents, also address PD-L1+ non-AML cells. By combining the high efficacy of T-cell engagers with immune checkpoint blockade in a single molecule, we expect to minimize irAEs associated with the systemic application of immune checkpoint inhibitors and suggest high therapeutic potential, particularly for patients with relapsed/ refractory AML.
引用
- Herrmann M, Krupka C, Deiser K, et al. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood. 2018. PMID: 30275109. doi:10.1182/blood-2018-05-849802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。